TNSN04022A1 - Compositions pharmaceutiques d'amlodipine et d'atorvastatine - Google Patents

Compositions pharmaceutiques d'amlodipine et d'atorvastatine

Info

Publication number
TNSN04022A1
TNSN04022A1 TNP2004000022A TNSN04022A TNSN04022A1 TN SN04022 A1 TNSN04022 A1 TN SN04022A1 TN P2004000022 A TNP2004000022 A TN P2004000022A TN SN04022 A TNSN04022 A TN SN04022A TN SN04022 A1 TNSN04022 A1 TN SN04022A1
Authority
TN
Tunisia
Prior art keywords
amlodipine
atorvastatin
compositions
pharmaceutically acceptable
acceptable salts
Prior art date
Application number
TNP2004000022A
Other languages
English (en)
Inventor
Laman Alani
Sadath Ulla Khan
Thomas Michael Macneil
Nouman Abdul-Hussain Muhammad
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of TNSN04022A1 publication Critical patent/TNSN04022A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

UNE COMPOSITION PHARMACEUTIQUE COMPRENANT DEUX CONSTITUANTS: (A) UN CONSTITUANT COMPRENANT DES GRANULES D'ATORVASTATINE OU DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN SUPPORT COMPRENANT UN AGENT ALCALINISANT QUI ENGENDRE UN PH SUPERIEUR A 5 ; ET (B) UN SECOND CONSTITUANT COMPRENANT DE L'AMLODIPINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN SUPPORT; A L'EXCLUSION D'UN AGENT ALCALINISANT; QUI ENGENDRE UN PH SUPERIEUR A 5; DANS LAQUELLE LES DEUX CONSTITUANTS SONT COMBINES POUR FORMER UNE COMPOSITION FINALE POUR UNE FORME POSOLOGIQUE SOLIDE; EST DECRITE; AINSI QUE DES PROCEDES POUR LA PREPARATION DE TELLES COMPOSITIONS; DES KITS CONTENANT CES COMPOSITIONS; ET UNE METHODE DE TRAITEMENT DE L'ANGINE DE POITRINE; DE L'ATHEROSCLEROSE; DE L'HYPERTENSION ET DE L'HYPERLIPIDEMIE ET/OU HYPERCHOLESTEROLEMIE ASSOCIEES; ET DES SYMPTOMES DE RISQUE CARDIAQUE AU MOYEN D'UNE QUANTITE THERAPEUTIQUEMENT EFFICACE DE LA COMPOSITION PHARMACEUTIQUE.
TNP2004000022A 2001-07-31 2004-01-30 Compositions pharmaceutiques d'amlodipine et d'atorvastatine TNSN04022A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30913301P 2001-07-31 2001-07-31
PCT/IB2002/002988 WO2003011283A1 (fr) 2001-07-31 2002-07-29 Compositions pharmaceutiques d'amlodipine et d'atorvastatine

Publications (1)

Publication Number Publication Date
TNSN04022A1 true TNSN04022A1 (fr) 2006-06-01

Family

ID=23196829

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2004000022A TNSN04022A1 (fr) 2001-07-31 2004-01-30 Compositions pharmaceutiques d'amlodipine et d'atorvastatine

Country Status (46)

Country Link
US (2) US20030114497A1 (fr)
EP (2) EP1852116A1 (fr)
JP (3) JP4020863B2 (fr)
KR (2) KR20040032148A (fr)
CN (2) CN101185646A (fr)
AP (1) AP1745A (fr)
AR (1) AR034925A1 (fr)
AT (1) ATE385793T1 (fr)
AU (1) AU2002355680B2 (fr)
BR (1) BR0211548A (fr)
CA (1) CA2444554C (fr)
CO (1) CO5540287A2 (fr)
CR (1) CR7219A (fr)
CY (1) CY1107245T1 (fr)
DE (1) DE60225014T2 (fr)
DK (1) DK1411923T3 (fr)
DO (1) DOP2002000445A (fr)
EA (1) EA006998B1 (fr)
EC (1) ECSP044965A (fr)
ES (1) ES2298381T3 (fr)
GE (1) GEP20063926B (fr)
GT (1) GT200200158A (fr)
HN (1) HN2002000198A (fr)
HR (1) HRP20040067A2 (fr)
HU (1) HUP0401569A2 (fr)
IL (1) IL159440A0 (fr)
IS (1) IS7089A (fr)
MA (1) MA27052A1 (fr)
MX (1) MXPA04000270A (fr)
MY (1) MY137519A (fr)
NI (1) NI200200095A (fr)
NO (1) NO20040405L (fr)
NZ (1) NZ530247A (fr)
OA (1) OA13300A (fr)
PA (1) PA8551701A1 (fr)
PE (1) PE20030324A1 (fr)
PL (1) PL368519A1 (fr)
PT (1) PT1411923E (fr)
RS (1) RS5304A (fr)
SG (1) SG143982A1 (fr)
SV (1) SV2003001189A (fr)
TN (1) TNSN04022A1 (fr)
UA (1) UA79750C2 (fr)
UY (1) UY27402A1 (fr)
WO (1) WO2003011283A1 (fr)
ZA (1) ZA200400659B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524615B2 (en) * 2001-02-21 2003-02-25 Kos Pharmaceuticals, Incorporated Controlled release pharmaceutical composition
BRPI0513396A (pt) * 2004-07-16 2008-05-06 Lek Pharmaceuticals produtos de degradação oxidativa de atorvastatina de cálcio
KR100881103B1 (ko) * 2004-09-28 2009-02-02 테바 파마슈티컬 인더스트리즈 리미티드 실질적으로 불순물을 함유하지 않는 아토르바스타틴 칼슘의형태를 제조하는 방법
US8367105B2 (en) 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
WO2006059217A1 (fr) * 2004-12-01 2006-06-08 Ranbaxy Laboratories Limited Formes posologiques solides stables d'amlodipine bezylate, et procedes d'elaboration correspondants
US20080305158A1 (en) * 2004-12-28 2008-12-11 Ranbaxy Laboratories Limited Methods For the Preparation of Stable Pharmaceutical Solid Dosage Forms of Atorvastatin and Amlodipine
MX2007011119A (es) * 2005-03-15 2007-11-14 Lupin Ltd Composiciones farmaceuticas de amlodipino y benazepril.
PT2000137E (pt) * 2006-03-29 2016-02-17 Kowa Co Agente redutor de triglicerídeos e agente melhorador de hiperinsulinismo
DE102006033723A1 (de) * 2006-07-21 2008-01-24 Bayer Technology Services Gmbh Formulierungen von Multikompartimenten-Granulaten für Wirkstoffe
KR100793321B1 (ko) * 2006-11-29 2008-01-11 사회복지법인 삼성생명공익재단 후각장애 치료 및 예방용 조성물
CN101433539A (zh) * 2007-11-12 2009-05-20 北京瑞康医药技术有限公司 含有烟酸氨氯地平和他汀类药物的治疗组合物
EP2070520A1 (fr) 2007-12-11 2009-06-17 LEK Pharmaceuticals D.D. Composition pharmaceutique comportant au moins un agent actif et un liant, qui gonfle dans un support acide
WO2009116061A2 (fr) * 2008-01-10 2009-09-24 Alkem Laboratories Ltd. Composition pharmaceutique stable, à usage oral, comprenant de l'atorvastatine
PT2165702E (pt) 2008-09-17 2012-02-07 Helm Ag Composições estáveis e rapidamente dissolvidas de candesartan cilexetil preparadas com granulação húmida
WO2010036600A1 (fr) * 2008-09-24 2010-04-01 Merck Sharp & Dohme Corp. Compositions pharmaceutiques d’atorvastatine
WO2011152803A1 (fr) * 2010-06-03 2011-12-08 Mahmut Bilgic Formulation hydrosoluble stable
CN107028926A (zh) 2011-08-26 2017-08-11 国立大学法人大阪大学 糖尿病性心血管并发症的预防/治疗剂
JP2013231011A (ja) * 2012-05-01 2013-11-14 Sawai Pharmaceutical Co Ltd アトルバスタチン含有医薬組成物およびそれを用いた口腔内崩壊錠
KR20140030505A (ko) * 2012-08-31 2014-03-12 한미약품 주식회사 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
KR20140028971A (ko) 2012-08-31 2014-03-10 한미약품 주식회사 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
KR101771766B1 (ko) * 2013-12-30 2017-08-28 알보젠코리아 주식회사 안지오텐신-Ⅱ 수용체 차단제 및 HMG-CoA 환원효소 저해제를 포함하는 약제학적 복합제제
US10350171B2 (en) 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same
CN109180701A (zh) * 2018-09-07 2019-01-11 中国药科大学 一种化合物2016a0c1药物组合物的共无定形物
KR102042626B1 (ko) 2019-06-26 2019-11-11 한미약품 주식회사 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
CN111689922B (zh) * 2020-07-17 2022-03-15 江西施美药业股份有限公司 一种苯磺酸左旋氨氯地平环合杂质的合成方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5149837A (en) * 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) * 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) * 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) * 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) * 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5248793A (en) * 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5103024A (en) * 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) * 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
WO1994016693A1 (fr) * 1993-01-19 1994-08-04 Warner-Lambert Company Formulation ci-981, orale, stable et son procede de preparation
US5385929A (en) * 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
SI9500173B (sl) * 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
DE69616808T2 (de) * 1995-07-17 2002-05-29 Warner Lambert Co Kristallines (r-(r*,r*))-2-(4-fluorphenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrol-1-heptancarbonsäure hemi calcium salz (atorvastatin)
PL186714B1 (pl) * 1995-11-02 2004-02-27 Warner Lambert Co Kompozycja farmaceutyczna do regulowania stężenialipidów do ssaka
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
EA002705B1 (ru) * 1997-08-29 2002-08-29 Пфайзер Продактс Инк. Комбинационная терапия, включающая в себя амлодипин и статиновое соединение
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
NZ503598A (en) * 1997-11-25 2002-06-28 Warner Lambert Co Hydroxylated gemfibrozil, atorvastatin and fluvastatin with antioxidant activity for inhibition of lipoprotein oxidation
SK15382001A3 (sk) * 1999-04-23 2002-05-09 R. Preston Mason Farmaceutický prostriedok obsahujúci amlodipín, spôsob liečenia a spôsob znižovania krvného tlaku
HN2000000050A (es) * 1999-05-27 2001-02-02 Pfizer Prod Inc Sal mutua de amlodipino y atorvastatina
US6835742B2 (en) * 2000-08-04 2004-12-28 R. Preston Mason Synergistic effect of amlodipine and atorvastatin on cholesterol crystal formation inhibition and aortic endothelial cell nitric oxide release

Also Published As

Publication number Publication date
HRP20040067A2 (en) 2005-02-28
UA79750C2 (en) 2007-07-25
MA27052A1 (fr) 2004-12-20
WO2003011283A1 (fr) 2003-02-13
NZ530247A (en) 2006-06-30
KR100674762B1 (ko) 2007-01-25
CN101185646A (zh) 2008-05-28
GEP20063926B (en) 2006-09-25
HN2002000198A (es) 2005-10-20
SG143982A1 (en) 2008-07-29
DE60225014T2 (de) 2008-06-12
MXPA04000270A (es) 2004-05-04
ATE385793T1 (de) 2008-03-15
AR034925A1 (es) 2004-03-24
GT200200158A (es) 2003-05-15
JP2007153908A (ja) 2007-06-21
NI200200095A (es) 2004-06-07
AP2004002963A0 (en) 2004-03-31
PL368519A1 (en) 2005-04-04
CO5540287A2 (es) 2005-07-29
KR20040032148A (ko) 2004-04-14
CA2444554C (fr) 2007-09-04
CN1617717A (zh) 2005-05-18
EP1411923A1 (fr) 2004-04-28
EP1852116A1 (fr) 2007-11-07
US20030114497A1 (en) 2003-06-19
DK1411923T3 (da) 2009-01-05
ES2298381T3 (es) 2008-05-16
DOP2002000445A (es) 2003-01-31
ECSP044965A (es) 2004-03-23
AP1745A (en) 2007-05-30
IL159440A0 (en) 2004-06-01
IS7089A (is) 2003-12-22
UY27402A1 (es) 2003-02-28
JP4020863B2 (ja) 2007-12-12
US20050107446A1 (en) 2005-05-19
EP1411923B1 (fr) 2008-02-13
MY137519A (en) 2009-02-27
JP2007314566A (ja) 2007-12-06
PA8551701A1 (es) 2003-02-14
BR0211548A (pt) 2004-07-13
DE60225014D1 (de) 2008-03-27
PT1411923E (pt) 2008-04-02
NO20040405L (no) 2004-03-08
HUP0401569A2 (hu) 2004-12-28
EA006998B1 (ru) 2006-06-30
KR20060054495A (ko) 2006-05-22
ZA200400659B (en) 2005-04-28
RS5304A (en) 2006-10-27
SV2003001189A (es) 2003-03-18
OA13300A (en) 2007-04-13
PE20030324A1 (es) 2003-04-03
CR7219A (es) 2004-03-24
AU2002355680B2 (en) 2007-11-15
CA2444554A1 (fr) 2003-02-13
CY1107245T1 (el) 2012-11-21
EA200400028A1 (ru) 2004-08-26
JP2005501051A (ja) 2005-01-13

Similar Documents

Publication Publication Date Title
TNSN04022A1 (fr) Compositions pharmaceutiques d'amlodipine et d'atorvastatine
TNSN98155A1 (fr) Associations de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation
TNSN98158A1 (fr) Associations pharmaceutiques d'amlodipine et d'une statine, et procede pour leur preparation
ME00545B (me) Terapeutske kombinacije koje sadrže amlodipin i atorvastatin
MA29731B1 (fr) Derives de pyridazinone utilises comme agonistes du recepteur de l'hormone tyroïdienne
TNSN98140A1 (fr) Derives d'indole inhibiteurs de cyclo-oxygenase, procede pour leur preparation et compositions pharmaceutiques les contenant
EA200000718A1 (ru) Композиции целекоксиба
TNSN01125A1 (fr) Compositions pharmaceutiques comprenant un inhibiteur de cetp et de l'atorvastatine
TNSN00256A1 (fr) Inhibiteurs non peptidiques de la liaison cellulaire sous la dependance de vla-4 utiles dans le traitement des maladies inflammatoires, auto-immunes et respiratoires, et compositions les contenant
TNSN03130A1 (fr) Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese
BE1002406A5 (fr) Compositions pharmaceutiques.
TNSN99132A1 (fr) Une composition pour la prevention et/ou le traitement de l'osteoporose ou des alterations dues au syndrome de menopause
TNSN97040A1 (fr) Compositions pharmaceutiques mixtes pour le traitement de l'osteoporose, et procede pour leur preparation.
TNSN99095A1 (fr) 4 - phenylpiperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97208A1 (fr) Prevention de la perte et restauration de la masse osseuse par certains agonistes des prostaglandines
CA2330500A1 (fr) Compositions pharmaceutiques gelifiables
MA30413B1 (fr) Nouvelles compositions pharmaceutiques faiblement dosees contenant du nimesulide, leur preparation et utilisation
FR2668064B1 (fr) Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
TNSN07145A1 (fr) Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
TR199802345T2 (xx) Siklooksijenaz-2-arac�l� hastal�klarda g�nde bir kez tatbikat i�in bile�imler.
MA26739A1 (fr) Sel mutuel d'amlodipine et d'atorvastatine, procede pour sa preparation et compositions pharmaceutiques les contenant
TNSN03085A1 (fr) Composition parenterale reconstituable contenant un inhibiteur de cox-2
MA28742B1 (fr) Derives de pyrido-pyrimidine, leur preparation, leur application en therapeutique
TNSN00113A1 (fr) Precurseurs medicamenteux mutuels d'amlodipine et d'atorvastatine, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2438654A1 (fr) Compose de 2-methyl-dihydropyridine, procedes pour son obtention et composition pharmaceutique contenant ce compose